

| 카탈로그 번호 | HB651226 |
|---|---|
| 종 반응성 | Human |
| 응용 분야 | ELISA, Bioactivity: FCM, Functional assay, Research in vivo |
| 숙주 종 | Human |
| 클론성 | Monoclonal |
| 이소타입 | IgG |
| 클론 ID | JMW-3B3 |
| 생물학적 활성 | Biotinylated JMW-3B3 (10 ug/mL) specifically detects sCTLA-4 in PBMC cell culture supernatants, and reveals no population-level difference in sCTLA-4 production between SLE patient and healthy donor PBMC stimulated with lupus-associated autoantigenic peptides [1]. JMW-3B3 (10 ug/mL; 5 days) blocks sCTLA-4 activity in PBMC from both healthy donors and SLE patients, with effects that vary by stimulant: it suppresses some pro-inflammatory and proliferative responses in healthy donors, while enhancing IL-10 production (and altering proliferation/cytokine profiles) in SLE patient PBMC, accentuating the inherent cytokine response differences between the two groups [1]. JMW-3B3 (20 ug/mL; overnight at 4°C) selectively binds intracellular sCTLA-4 in G-361 human malignant melanoma epithelial cells, but does not detect sCTLA-4 in A-375 human malignant melanoma epithelial cells [2]. JMW-3B3 (10 ug/mL; 5 days) enhances IFN-γ production from melanoma patient PBMC stimulated with a low dose (0.02 ug/mL) of anti-CD3 mAb for 5 days, relative to ipilimumab treatment [2]. JMW-3B3 (10 ug/mL; 5 days) enhances IL-17A production from healthy donor PBMC stimulated with a high dose (1 ug/mL) of anti-CD3 mAb for 5 days, relative to ipilimumab treatment [2]. |
| 타겟 | CD152, CTLA-4, CTLA4, Cytotoxic T-lymphocyte protein 4, Cytotoxic T-lymphocyte-associated antigen 4 |
| 내독소 수준 | < 10 EU/mg |
| 순도 | >95% as determined by SDS-PAGE. |
| 정제 | Protein A/G purified from cell culture supernatant. |
| 등록번호 | P16410 |
| 형태 | Liquid |
| 저장 완충액 | 0.01M PBS pH 7.4. 데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요. |
| 안정성 및 저장 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 대체 이름 | JMW-3B3, JMW3B3, JMW3B3 |
| 배경 | Cytotoxic T-lymphocyte protein 4 (CD152/CTLA4) is a ~24 kDa protein. Inhibitory receptor acting as a major negative regulator of T-cell responses. Acts as a decoy receptor: the affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28. CD152 is the therapeutic target of ipilimumab (Yervoy). 1. Schwartz, JC. et al. (2001) Nature 410, 604-8. PMID: 11279501 2. Stamper, CC. et al. (2001) Nature 410, 608-11. PMID: 11279502 3. Teft, WA. et al. (2006) Annual review of immunology 24, 65-97. PMID: 16551244 4. Linsley, PS. et al. (1991) The Journal of experimental medicine 174, 561-9. PMID: 1714933 5. Zheng, Y. et al. (2008) Journal of immunology (Baltimore, Md. : 1950) 181, 1683-91. PMID: 18641304 6. Ramagopal, UA. et al. (2017) Proceedings of the National Academy of Sciences of the United States of America 114, E4223-E4232. PMID: 28484017 |
| 참고 문헌 | 1. Dahal LN, et al. Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus. Arthritis Res Ther. 2016;18:180. Published 2016 Aug 4. [HB651226] 2. Khanolkar RC, et al. TGFβ2 Induces the Soluble Isoform of CTLA-4 - Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma. Front Immunol. 2022;12:763877. Published 2022 Jan 5. [HB651226] |
| 참고사항 | For research use only. Not suitable for clinical or therapeutic use. |

SDS-PAGE for Research Grade Anti-Human CD152/CTLA4 (JMW-3B3)


+86-027-65523339
중국 우한시 심둔사로 666번지 C동, 우한, 430206

中文
English
한국어
日本語
Español
Français
Русский